Abstract
Inhibitory Effect of Pre-Immunized CBA Spleen Cells on Transplants of A-strain Mouse Mammary Carcinoma in (CBA × A) F 1 Hybrid Recipients
Highlights
Sixty adult (20-25 g.) female (CBA x A) F1 hybrid mice were each given on Day 0 a subcutaneous injection of 20 million cells prepared from a single first-generation tumour transplant in an A-strain female mouse which had itself received an injection of 20 million cells from a spontaneous A-strain mammary carcinoma (No LXIX) 35 days previously
In the group (R3) which received three spleen cell injections tumours appeared in all the mice but subsequently regressed completely in two of them and have not since recurred; in the remainder the tumours grew progressively but again there was a sudden decrease in growth rate at Day 14, which was more marked than that observed in group R2
The results show that the growth of transplants of an A-strain mammary carcinoma in (CBA x A) F1 hybrid hosts may, under the conditions of the experiment, be inhibited by the injection of spleen cells from CBA donors immunized against the tumour
Summary
Sixty adult (20-25 g.) female (CBA x A) F1 hybrid mice were each given on Day 0 a subcutaneous injection of 20 million cells (of which approximately 20 per cent were non-viable as judged by the trypan blue test) prepared from a single. First-generation tumour transplant in an A-strain female mouse which had itself received an injection of 20 million cells from a spontaneous A-strain mammary carcinoma (No LXIX) 35 days previously. These mice were allocated at random into three groups of predetermined size designated R0, RI and R3, containing 12, 16 and 32 animals respectively. The RI mice received a single intravenous injection of 100 million spleen cells on Day + 7 from D7 donors. Total and non-viable cell counts were made in a haemocytometer after diluting the suspension with 2 per cent acetic acid in water and 0O05 per cent trypan blue in Hanks' solution respectively
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
